BioLineRx (NASDAQ:BLRX) had its price target increased by stock analysts at Maxim Group from $5.00 to $10.00 in a research report issued on Tuesday, The Fly reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price objective indicates a potential upside of 109.64% from the company’s previous close.
BLRX has been the topic of a number of other research reports. Zacks Investment Research downgraded shares of BioLineRx from a “hold” rating to a “sell” rating in a research report on Wednesday, February 24th. HC Wainwright decreased their price target on shares of BioLineRx from $22.00 to $19.00 and set a “buy” rating for the company in a research note on Monday, March 1st.
NASDAQ:BLRX traded up $1.58 during mid-day trading on Tuesday, hitting $4.77. 7,426,721 shares of the company’s stock were exchanged, compared to its average volume of 1,608,911. BioLineRx has a fifty-two week low of $1.40 and a fifty-two week high of $4.23. The company has a current ratio of 2.05, a quick ratio of 2.04 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $204.12 million, a P/E ratio of -2.13 and a beta of 2.08. The company has a 50 day simple moving average of $2.90 and a 200-day simple moving average of $2.71.
Several hedge funds have recently bought and sold shares of BLRX. Rhumbline Advisers purchased a new position in shares of BioLineRx during the fourth quarter valued at approximately $36,000. Thomasville National Bank lifted its stake in BioLineRx by 62.6% during the 4th quarter. Thomasville National Bank now owns 20,325 shares of the biotechnology company’s stock valued at $51,000 after acquiring an additional 7,825 shares in the last quarter. Game Plan Financial Advisors LLC purchased a new position in BioLineRx during the 1st quarter worth $74,000. LPL Financial LLC grew its stake in shares of BioLineRx by 154.1% in the 4th quarter. LPL Financial LLC now owns 42,876 shares of the biotechnology company’s stock worth $108,000 after acquiring an additional 26,000 shares in the last quarter. Finally, Morgan Stanley grew its stake in shares of BioLineRx by 36.0% in the 3rd quarter. Morgan Stanley now owns 768,335 shares of the biotechnology company’s stock worth $1,260,000 after acquiring an additional 203,221 shares in the last quarter. Institutional investors own 17.46% of the company’s stock.
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions.
Featured Story: Analyst Ratings Trading
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.